The stocks in the marijuana sector have pretty much traded in sync with the broad market since the March bottom, climbing strongly to late-May or early-June peaks and consolidating those gains since, with many stocks pulling back to sensible support levels.
Read More
Buying Opportunities
The last few weeks have brought a much-needed market correction—much-needed because after advancing for eleven weeks from the COVID-19 bottom, the market was extended, and some segments of the investing world were positively giddy. But now that the correction has done its capped...
Read More
The marijuana sector looks increasingly healthy, as the leading companies continue to post triple-digit growth rates and the leading stocks continue to climb higher.
Read More
The Trend Strengthens!
Canada was first, but the U.S. will dominate. That’s not exactly a surprise, but the evidence is now piling up, most recently in the form of some terrific first quarter reports by U.S. marijuana companies while the Canadians continue to cut and...
Read More
While the broad market enjoyed a powerful upmove yesterday, the marijuana sector was even stronger, with the Marijuana Index surging 15%.
Read More
As coronavirus matters continue to dominate the headlines and the world works toward slowly reopening, the action of marijuana stocks continues to impress—and with good reason.
Read More
The Trend Turns Up
First, I want to welcome our many new readers, who joined following our 4/20 promotion. My goal is to help you develop long-term winning investments in the leaders of this mass-market growth industry.
But it won’t be easy. Sometimes these stocks red-hot;...
Read More
From top to bottom, the Marijuana Index fell 88% from early 2018 to last month’s market low, and now the recovery has begun.
Read More
Uncharted Territory—But We Have A Compass
As of Monday, we’d experienced the market’s quickest 30% drop ever. Just 22 days from top to bottom.
Yesterday, the Dow had its best up day in 87 years—up 11%!
And tomorrow?
Well, as the headline says, we’re in uncharted territory. one...
Read More
With the market down more than 30% since it peaked a month ago, it’s worth reviewing the reasons for the quick crash.
Read More
The good news is that the amount of cannabis intercepted along all U.S. borders has fallen by 89% since 2011, from 2.5 million pounds per year to about 270,000 pounds in 2019.
Read More
Where’s The Bottom?
I’ve been through a lot of nasty markets in the 34 years I’ve spent at Cabot—some of them infamous, like 1987 and 2000 and 2008, and some of them less so, like 1990 and 1997 and 2002—and while I can’t say found...
Read More
Marijuana stocks have been building a meaningful bottom since November—and there are good and bad aspects to that.
Read More
Marijuana stocks remain under pressure (with a few exceptions), as firms struggle for growth and profitability.
Read More
Coronavirus Takes Center Stage—and Marijuana Stocks Don’t Care!
I’m in no way a medical professional, so I have nothing useful to say about coronavirus that you haven’t heard elsewhere. But I do have a few thoughts on how the market has reacted to this than...
Read More
The stocks in are our portfolio are gradually looking healthier, as bargain hunters invest more carefully, focusing on the stocks with the best prospects for real revenue growth and real earnings.
Read More
The broad market remains strong, while the cannabis sector remains stuck in the mud—in general.
Read More
Ready For The Big Rebound
The end of the year always brings opportunities for investors who want to speculate on which stocks will rebound best, and this year, there’s no question that cannabis stocks, which are down 46% since the start of the year, near...
Read More
Marijuana stocks remain under pressure, as year-end tax selling pressures continue, but the marijuana industry is booming, as evidenced not only by recent quarterly reports but also by the growth of MJBizCon, the industry’s leading conference.
Read More
One of our stocks is down sharply today on big volume following a report by short-sellers Grizzly Reports that accuses the company and insiders of numerous improprieties, ranging from political cronyism and corruption to overvaluation of assets to misrepresentation of financial relationships.
Read More